Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3BNC117-LS, 10-1074-LS, and N-803 in HIV during ATI
NCT05245292Phase 1Completed
- Sponsor
- The Rockefeller University
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons, Anti-infectious Disease mAbs, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Teropavimab, zinlirvimab and nogapendekin alfa inbakicept in human immunodeficiency virus infection (HIV), sponsored by The Rockefeller University. Primary endpoints: Treatment-related Grade 3 adverse events and serious adverse events at 72 weeks, Any serious adverse events at 72 weeks and 4 more. Started Dec 2022; status: completed.
02
Drugs
Teropavimabzinlirvimabnogapendekin alfa inbakicept
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05245292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245292.